This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

Andrew Feigin and Ralf Reilmann, AD/PD 2021: The PROOF-HD Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 17th 2021

touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study.

The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome on Function in Huntington Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.

Questions:

  1. Could you tell us a little about pridopidine and its mechanism of action? (1:00)
  2. What have clinical studies to date taught us about the clinical utility of pridopidine in Huntington’s disease, and what have been the limitations of these studies? (3:43)
  3. How have previous data been used to optimise the design of the PROOF-HD trial? (12:41)

Disclosures: Andrew Feigin has served as a consultant for NeuExcell, Prilenia, Stealth, and Voyager. Ralf Reilmann has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AD/PD Virtual 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup